Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy with or without docetaxel in treating patients who have metastatic prostate cancer.

Key facts

Study ID

NCT00045227

Run by

National Cancer Institute (NCI)

Starts

2002-08-01

Expected to finish

2007-10-01

Last updated by the study team

2013-06-19

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.